XML 33 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Pay vs Performance Disclosure |  |  |  |  |
Pay vs Performance Disclosure, Table |
|  | SCT Total For PEO #1 |  | CAP to PEO #1 |  | SCT Total For PEO #2 |  | CAP to PEO #2 |  | SCT Total For PEO #3 |  | CAP to PEO #3 |  | Average SCT |  | Average |  | Value of Initial Fixed $100 Investment Based on TSR of: |  | Net Income |  | Adjusted EBITDA (6) |
Year |  | Brandon K. Sim, M.S.(1)(2) |  | Thomas S. Lam, M.D., M.P.H (1)(2) |  | Kenneth Sim, M.D.(1)(2) |  | Total For Non-PEO NEOs(3) |  | CAP To Non-PEO NEOs(2)(3) |  | ASTH (4) |  | S&P 500 Healthcare Index(4)(5) |  | (In millions) |
2024 |  | $ | 18,242,585 |  | $ | 16,942,570 |  | $ | 2,843,062 |  | $ | 2,279,000 |  | $ | — |  | $ | — |  | $ | 6,666,617 |  | $ | 3,644,213 |  | $ | 171 |  | $ | 147 |  | $ | 50 |  | $ | 170 |
2023 |  | $ | 14,311,250 |  | $ | 13,561,755 |  | $ | 5,217,562 |  | $ | 4,314,127 |  | $ | — |  | $ | — |  | $ | 3,827,960 |  | $ | 3,356,039 |  | $ | 208 |  | $ | 143 |  | $ | 58 |  | $ | 147 |
2022 |  | $ | 15,302,775 |  | $ | 997,261 |  | $ | 1,487,709 |  | $ | (5,920,199 | ) | $ | — |  | $ | — |  | $ | 1,667,352 |  | $ | (574,925 | ) | $ | 161 |  | $ | 140 |  | $ | 46 |  | $ | 140 |
2021 |  | $ | 9,006,157 |  | $ | 15,536,119 |  | $ | 6,857,194 |  | $ | 16,090,110 |  | $ | 6,863,527 |  | $ | 16,096,441 |  | $ | 688,309 |  | $ | 1,155,454 |  | $ | 399 |  | $ | 143 |  | $ | 46 |  | $ | 134 |
2020 |  | $ | — |  | $ | — |  | $ | 2,515,142 |  | $ | 2,412,546 |  | $ | 2,521,773 |  | $ | 2,419,178 |  | $ | 685,422 |  | $ | 695,307 |  | $ | 99 |  | $ | 113 |  | $ | 122 |  | $ | 103 |
| (1) | The PEOs shown in the table above for each applicable fiscal year are as follows:
Year |  | PEOs
2024 |  | Brandon K. Sim, M.S. and Thomas Lam, M.D., M.P.H
2023 |  | Brandon K. Sim, M.S. and Thomas Lam, M.D., M.P.H
2022 |  | Brandon K. Sim, M.S. and Thomas Lam, M.D., M.P.H
2021 |  | Kenneth Sim, M.D., Brandon K. Sim, M.S., and Thomas Lam, M.D., M.P.H.
2020 |  | Kenneth Sim, M.D. and Thomas Lam, M.D., M.P.H
| (2) | As the valuation methods for compensation actually paid (“CAP”) required by the SEC differ from those required in the Summary Compensation Table (“SCT”), the tables below provide a reconciliation of the SCT amounts to the CAP amounts in the Pay Versus Performance table for the PEOs and Non-PEO NEOs for each of the last five fiscal years.
| (3) | The Non-PEO NEOs shown in the table above for each applicable fiscal year are as follows:
Year |  | Non-PEO NEOs
2024 |  | Kenneth Sim, M.D., Chandan Basho, M.B.A., Dinesh Kumar, M.D., and Albert Young, M.D., M.P.H.
2023 |  | Kenneth Sim, M.D., Chandan Basho, M.B.A., and Albert Young, M.D., M.P.H.
2022 |  | Kenneth Sim, M.D., Chandan Basho, M.B.A., Albert Young, M.D., M.P.H., and Eric Chin
2021 |  | Eric Chin and Albert Young, M.D., M.P.H.
2020 |  | Eric Chin, Brandon K. Sim M.S., Adrian Vazquez, M.D., and Albert Young, M.D., M.P.H.
| (4) | Pursuant to the SEC rules, total stockholder return, or TSR, reflects an initial investment of $100 on December 31, 2019.
| (5) | The peer group of the listed fiscal year consists of the S&P 500 Healthcare Index.
| (6) | The company selected measure is Adjusted EBITDA.
Summary Compensation Table to Compensation Actually Paid Reconciliation Table
| PEO #1 Brandon K. Sim, M.S.
| 2024 |  | 2023 |  | 2022 |  | 2021
Total Reported in Summary Compensation Table (SCT) | $ | 18,242,585 |  | $ | 14,311,250 |  | $ | 15,302,775 |  | $ | 9,006,157
Less, Value of Stock & Option Awards Reported in SCT(1) | (15,893,226) |  | (12,499,943) |  | (13,567,843) |  | (7,816,831)
Plus, Year-End Value of Awards Granted in Fiscal Year That Are Unvested and Outstanding | 7,192,781 |  | 9,243,092 |  | 6,778,744 |  | 13,976,639
Plus, Change in Fair Value of Prior Year Awards That Are Outstanding and Unvested | 5,477,073 |  | 1,821,347 |  | (5,032,202) |  | —
Plus, FMV of Awards Granted this Year That Vested This Year | 826,136 |  | 527,597 |  | — |  | —
Plus, Change in Fair Value (from Prior Year-End) of Prior Year Awards That Vested This Year | 1,097,221 |  | 158,412 |  | (2,484,213) |  | 370,154
Less, Prior Year Fair Value of Prior Year Awards That Failed to Vest this Year | — |  | — |  | — |  | —
Plus, Dividends or Earnings Paid on Awards Not Otherwise Reflected in Fair Value | — |  | — |  | — |  | —
Compensation Actually Paid | $ | 16,942,570 |  | $ | 13,561,755 |  | $ | 997,261 |  | $ | 15,536,119
| PEO #2 Thomas S. Lam, M.D., M.P.H.
| 2024 |  | 2023 |  | 2022 |  | 2021 |  | 2020
Total Reported in Summary Compensation Table (SCT) | $ | 2,843,062 |  | $ | 5,217,562 |  | $ | 1,487,709 |  | $ | 6,857,194 |  | $ | 2,515,142
Less, Value of Stock & Option Awards Reported in SCT(1) | (1,878,400) |  | (3,253,500) |  | — |  | (5,777,307) |  | (1,450,003)
Plus, Year-End Value of Awards Granted in Fiscal Year That Are Unvested and Outstanding | 420,389 |  | 2,298,000 |  | — |  | 5,875,821 |  | 1,486,990
Plus, Change in Fair Value of Prior Year Awards That Are Outstanding and Unvested | 539,700 |  | 171,330 |  | (3,852,379) |  | 4,920,552 |  | (67,429)
Plus, FMV of Awards Granted this Year That Vested this Year | — |  | — |  | — |  | — |  | —
Plus, Change in Fair Value (from Prior Year-End) of Prior Year Awards That Vested This Year | 354,249 |  | (119,265) |  | (3,555,529) |  | 4,213,850 |  | (72,154)
Less, Prior Year Fair Value of Prior Year Awards That Failed to Vest This Year | — |  | — |  | — |  | — |  | —
Plus, Dividends or Earnings Paid on Awards not Otherwise Reflected in Fair Value | — |  | — |  | — |  | — |  | —
Compensation Actually Paid | $ | 2,279,000 |  | $ | 4,314,127 |  | $ | (5,920,199) |  | $ | 16,090,110 |  | $ | 2,412,546
| PEO #3 Kenneth Sim, M.D.
| 2021 |  | 2020
Total Reported in Summary Compensation Table (SCT) | $ | 6,863,527 |  | $ | 2,521,773
Less, Value of Stock & Option Awards Reported in SCT(1) | (5,777,307) |  | (1,450,003)
Plus, Year-End Value of Awards Granted in Fiscal Year That Are Unvested and Outstanding | 5,875,819 |  | 1,486,991
Plus, Change in Fair Value of Prior Year Awards That Are Outstanding and Unvested | 4,920,552 |  | (67,429)
Plus, FMV of Awards Granted this Year That Vested This Year | — |  | —
Plus, Change in Fair Value (from Prior Year-End) of Prior Year awards That Vested This Year | 4,213,850 |  | (72,154)
Less, Prior Year Fair Value of Prior Year awards That Failed to Vest This Year | — |  | —
Plus, Dividends or Earnings Paid on Awards not Otherwise Reflected in Fair Value | — |  | —
Compensation Actually Paid | $ | 16,096,441 |  | $ | 2,419,178
| Average NEOs
| 2024 |  | 2023 |  | 2022 |  | 2021 |  | 2020
Total Reported in Summary Compensation Table (SCT) | $ | 6,666,617 |  | $ | 3,827,960 |  | $ | 1,667,352 |  | $ | 688,309 |  | $ | 685,422
Less, Value of Stock & Option Awards Reported in SCT(1) | (5,573,539) |  | (2,617,300) |  | (880,452) |  | (205,730) |  | (204,895)
Plus, Year-End Value of Awards Granted in Fiscal Year That Are Unvested and Outstanding | 2,299,412 |  | 1,818,867 |  | 524,690 |  | 652,802 |  | 107,514
Plus, Change in Fair Value of Prior Year Awards That Are Outstanding and Unvested | 25,600 |  | 180,624 |  | (956,215) |  | 17,308 |  | —
Plus, FMV of Awards Granted This Year That Vested This Year | 93,191 |  | 155,544 |  | 77,967 |  | — |  | 107,266
Plus, Change in Fair Value (from Prior Year-End) of Prior Year awards That Vested This year | 132,932 |  | (9,656) |  | (1,008,267) |  | 2,765 |  | —
Less, Prior Year Fair Value of Prior Year awards That Failed to Vest This Year | — |  | — |  | — |  | — |  | —
Plus, Dividends or Earnings Paid on Awards Not Otherwise Reflected in Fair Value | — |  | — |  | — |  | — |  | —
Compensation Actually Paid | $ | 3,644,213 |  | $ | 3,356,039 |  | $ | (574,925) |  | $ | 1,155,454 |  | $ | 695,307
| (1) | Stock option fair values are calculated at each measurement date using a Black-Scholes valuation model, consistent with the approach used to value the awards at the grant date. Stock option fair values as of each measurement date were determined using updated assumptions (the closing stock price of our common stock as of the measurement date, risk-free interest rate, expected life, expected volatility of the price of our common stock, and expected dividend yield) and fair value increases are primarily driven by an increase in the price of the Company’s common stock.
Company Selected Measure Name | Adjusted EBITDA |  |  |  |
Named Executive Officers, Footnote |
| (1) | The PEOs shown in the table above for each applicable fiscal year are as follows:
Year |  | PEOs
2024 |  | Brandon K. Sim, M.S. and Thomas Lam, M.D., M.P.H
2023 |  | Brandon K. Sim, M.S. and Thomas Lam, M.D., M.P.H
2022 |  | Brandon K. Sim, M.S. and Thomas Lam, M.D., M.P.H
2021 |  | Kenneth Sim, M.D., Brandon K. Sim, M.S., and Thomas Lam, M.D., M.P.H.
2020 |  | Kenneth Sim, M.D. and Thomas Lam, M.D., M.P.H
| (3) | The Non-PEO NEOs shown in the table above for each applicable fiscal year are as follows:
Year |  | Non-PEO NEOs
2024 |  | Kenneth Sim, M.D., Chandan Basho, M.B.A., Dinesh Kumar, M.D., and Albert Young, M.D., M.P.H.
2023 |  | Kenneth Sim, M.D., Chandan Basho, M.B.A., and Albert Young, M.D., M.P.H.
2022 |  | Kenneth Sim, M.D., Chandan Basho, M.B.A., Albert Young, M.D., M.P.H., and Eric Chin
2021 |  | Eric Chin and Albert Young, M.D., M.P.H.
2020 |  | Eric Chin, Brandon K. Sim M.S., Adrian Vazquez, M.D., and Albert Young, M.D., M.P.H.
Peer Group Issuers, Footnote |
| (5) | The peer group of the listed fiscal year consists of the S&P 500 Healthcare Index.
Adjustment To PEO Compensation, Footnote |
| (1) | The PEOs shown in the table above for each applicable fiscal year are as follows:
Year |  | PEOs
2024 |  | Brandon K. Sim, M.S. and Thomas Lam, M.D., M.P.H
2023 |  | Brandon K. Sim, M.S. and Thomas Lam, M.D., M.P.H
2022 |  | Brandon K. Sim, M.S. and Thomas Lam, M.D., M.P.H
2021 |  | Kenneth Sim, M.D., Brandon K. Sim, M.S., and Thomas Lam, M.D., M.P.H.
2020 |  | Kenneth Sim, M.D. and Thomas Lam, M.D., M.P.H
Summary Compensation Table to Compensation Actually Paid Reconciliation Table
| PEO #1 Brandon K. Sim, M.S.
| 2024 |  | 2023 |  | 2022 |  | 2021
Total Reported in Summary Compensation Table (SCT) | $ | 18,242,585 |  | $ | 14,311,250 |  | $ | 15,302,775 |  | $ | 9,006,157
Less, Value of Stock & Option Awards Reported in SCT(1) | (15,893,226) |  | (12,499,943) |  | (13,567,843) |  | (7,816,831)
Plus, Year-End Value of Awards Granted in Fiscal Year That Are Unvested and Outstanding | 7,192,781 |  | 9,243,092 |  | 6,778,744 |  | 13,976,639
Plus, Change in Fair Value of Prior Year Awards That Are Outstanding and Unvested | 5,477,073 |  | 1,821,347 |  | (5,032,202) |  | —
Plus, FMV of Awards Granted this Year That Vested This Year | 826,136 |  | 527,597 |  | — |  | —
Plus, Change in Fair Value (from Prior Year-End) of Prior Year Awards That Vested This Year | 1,097,221 |  | 158,412 |  | (2,484,213) |  | 370,154
Less, Prior Year Fair Value of Prior Year Awards That Failed to Vest this Year | — |  | — |  | — |  | —
Plus, Dividends or Earnings Paid on Awards Not Otherwise Reflected in Fair Value | — |  | — |  | — |  | —
Compensation Actually Paid | $ | 16,942,570 |  | $ | 13,561,755 |  | $ | 997,261 |  | $ | 15,536,119
| PEO #2 Thomas S. Lam, M.D., M.P.H.
| 2024 |  | 2023 |  | 2022 |  | 2021 |  | 2020
Total Reported in Summary Compensation Table (SCT) | $ | 2,843,062 |  | $ | 5,217,562 |  | $ | 1,487,709 |  | $ | 6,857,194 |  | $ | 2,515,142
Less, Value of Stock & Option Awards Reported in SCT(1) | (1,878,400) |  | (3,253,500) |  | — |  | (5,777,307) |  | (1,450,003)
Plus, Year-End Value of Awards Granted in Fiscal Year That Are Unvested and Outstanding | 420,389 |  | 2,298,000 |  | — |  | 5,875,821 |  | 1,486,990
Plus, Change in Fair Value of Prior Year Awards That Are Outstanding and Unvested | 539,700 |  | 171,330 |  | (3,852,379) |  | 4,920,552 |  | (67,429)
Plus, FMV of Awards Granted this Year That Vested this Year | — |  | — |  | — |  | — |  | —
Plus, Change in Fair Value (from Prior Year-End) of Prior Year Awards That Vested This Year | 354,249 |  | (119,265) |  | (3,555,529) |  | 4,213,850 |  | (72,154)
Less, Prior Year Fair Value of Prior Year Awards That Failed to Vest This Year | — |  | — |  | — |  | — |  | —
Plus, Dividends or Earnings Paid on Awards not Otherwise Reflected in Fair Value | — |  | — |  | — |  | — |  | —
Compensation Actually Paid | $ | 2,279,000 |  | $ | 4,314,127 |  | $ | (5,920,199) |  | $ | 16,090,110 |  | $ | 2,412,546
| PEO #3 Kenneth Sim, M.D.
| 2021 |  | 2020
Total Reported in Summary Compensation Table (SCT) | $ | 6,863,527 |  | $ | 2,521,773
Less, Value of Stock & Option Awards Reported in SCT(1) | (5,777,307) |  | (1,450,003)
Plus, Year-End Value of Awards Granted in Fiscal Year That Are Unvested and Outstanding | 5,875,819 |  | 1,486,991
Plus, Change in Fair Value of Prior Year Awards That Are Outstanding and Unvested | 4,920,552 |  | (67,429)
Plus, FMV of Awards Granted this Year That Vested This Year | — |  | —
Plus, Change in Fair Value (from Prior Year-End) of Prior Year awards That Vested This Year | 4,213,850 |  | (72,154)
Less, Prior Year Fair Value of Prior Year awards That Failed to Vest This Year | — |  | —
Plus, Dividends or Earnings Paid on Awards not Otherwise Reflected in Fair Value | — |  | —
Compensation Actually Paid | $ | 16,096,441 |  | $ | 2,419,178
| (1) | Stock option fair values are calculated at each measurement date using a Black-Scholes valuation model, consistent with the approach used to value the awards at the grant date. Stock option fair values as of each measurement date were determined using updated assumptions (the closing stock price of our common stock as of the measurement date, risk-free interest rate, expected life, expected volatility of the price of our common stock, and expected dividend yield) and fair value increases are primarily driven by an increase in the price of the Company’s common stock.
Non-PEO NEO Average Total Compensation Amount | $ 6,666,617 | $ 3,827,960 | $ 1,667,352 | $ 688,309 | $ 685,422
Non-PEO NEO Average Compensation Actually Paid Amount | $ 3,644,213 | 3,356,039 | (574,925) | 1,155,454 | 695,307
Adjustment to Non-PEO NEO Compensation Footnote |
| (3) | The Non-PEO NEOs shown in the table above for each applicable fiscal year are as follows:
Year |  | Non-PEO NEOs
2024 |  | Kenneth Sim, M.D., Chandan Basho, M.B.A., Dinesh Kumar, M.D., and Albert Young, M.D., M.P.H.
2023 |  | Kenneth Sim, M.D., Chandan Basho, M.B.A., and Albert Young, M.D., M.P.H.
2022 |  | Kenneth Sim, M.D., Chandan Basho, M.B.A., Albert Young, M.D., M.P.H., and Eric Chin
2021 |  | Eric Chin and Albert Young, M.D., M.P.H.
2020 |  | Eric Chin, Brandon K. Sim M.S., Adrian Vazquez, M.D., and Albert Young, M.D., M.P.H.
| Average NEOs
| 2024 |  | 2023 |  | 2022 |  | 2021 |  | 2020
Total Reported in Summary Compensation Table (SCT) | $ | 6,666,617 |  | $ | 3,827,960 |  | $ | 1,667,352 |  | $ | 688,309 |  | $ | 685,422
Less, Value of Stock & Option Awards Reported in SCT(1) | (5,573,539) |  | (2,617,300) |  | (880,452) |  | (205,730) |  | (204,895)
Plus, Year-End Value of Awards Granted in Fiscal Year That Are Unvested and Outstanding | 2,299,412 |  | 1,818,867 |  | 524,690 |  | 652,802 |  | 107,514
Plus, Change in Fair Value of Prior Year Awards That Are Outstanding and Unvested | 25,600 |  | 180,624 |  | (956,215) |  | 17,308 |  | —
Plus, FMV of Awards Granted This Year That Vested This Year | 93,191 |  | 155,544 |  | 77,967 |  | — |  | 107,266
Plus, Change in Fair Value (from Prior Year-End) of Prior Year awards That Vested This year | 132,932 |  | (9,656) |  | (1,008,267) |  | 2,765 |  | —
Less, Prior Year Fair Value of Prior Year awards That Failed to Vest This Year | — |  | — |  | — |  | — |  | —
Plus, Dividends or Earnings Paid on Awards Not Otherwise Reflected in Fair Value | — |  | — |  | — |  | — |  | —
Compensation Actually Paid | $ | 3,644,213 |  | $ | 3,356,039 |  | $ | (574,925) |  | $ | 1,155,454 |  | $ | 695,307
| (1) | Stock option fair values are calculated at each measurement date using a Black-Scholes valuation model, consistent with the approach used to value the awards at the grant date. Stock option fair values as of each measurement date were determined using updated assumptions (the closing stock price of our common stock as of the measurement date, risk-free interest rate, expected life, expected volatility of the price of our common stock, and expected dividend yield) and fair value increases are primarily driven by an increase in the price of the Company’s common stock.
Compensation Actually Paid vs. Total Shareholder Return |  |  |  |  |
Compensation Actually Paid vs. Net Income |  |  |  |  |
Compensation Actually Paid vs. Company Selected Measure |  |  |  |  |
Total Shareholder Return Vs Peer Group |  |  |  |  |
Tabular List, Table |
Most Important Financial Performance Measures
Adjusted EBITDA
Revenue
Total Shareholder Return Amount | $ 171 | 208 | 161 | 399 | 99
Peer Group Total Shareholder Return Amount | 147 | 143 | 140 | 143 | 113
Net Income (Loss) | $ 50,000,000 | $ 58,000,000 | $ 46,000,000 | $ 46,000,000 | $ 122,000,000
Company Selected Measure Amount | 170,000,000 | 147,000,000 | 140,000,000 | 134,000,000 | 103,000,000
Measure:: 1 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Adjusted EBITDA |  |  |  |
Non-GAAP Measure Description |
| (6) | The company selected measure is Adjusted EBITDA.
Measure:: 2 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Revenue |  |  |  |
Brandon K. Sim [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
PEO Total Compensation Amount | $ 18,242,585 | $ 14,311,250 | $ 15,302,775 | $ 9,006,157 |
PEO Actually Paid Compensation Amount | $ 16,942,570 | 13,561,755 | 997,261 | 15,536,119 |
PEO Name | Brandon K. Sim |  |  |  |
Thomas S. Lam [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
PEO Total Compensation Amount | $ 2,843,062 | 5,217,562 | 1,487,709 | 6,857,194 | 2,515,142
PEO Actually Paid Compensation Amount | $ 2,279,000 | 4,314,127 | (5,920,199) | 16,090,110 | 2,412,546
PEO Name | Thomas Lam |  |  |  |
Kenneth Sim [Member] |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
PEO Total Compensation Amount |  |  |  | 6,863,527 | 2,521,773
PEO Actually Paid Compensation Amount |  |  |  | 16,096,441 | 2,419,178
PEO | Brandon K. Sim [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (15,893,226) | (12,499,943) | (13,567,843) | (7,816,831) |
PEO | Brandon K. Sim [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 7,192,781 | 9,243,092 | 6,778,744 | 13,976,639 |
PEO | Brandon K. Sim [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 5,477,073 | 1,821,347 | (5,032,202) |  |
PEO | Brandon K. Sim [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 826,136 | 527,597 |  |  |
PEO | Brandon K. Sim [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 1,097,221 | 158,412 | (2,484,213) | 370,154 |
PEO | Brandon K. Sim [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |
PEO | Brandon K. Sim [Member] | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |
PEO | Thomas S. Lam [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (1,878,400) | (3,253,500) |  | (5,777,307) | (1,450,003)
PEO | Thomas S. Lam [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 420,389 | 2,298,000 |  | 5,875,821 | 1,486,990
PEO | Thomas S. Lam [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 539,700 | 171,330 | (3,852,379) | 4,920,552 | (67,429)
PEO | Thomas S. Lam [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |
PEO | Thomas S. Lam [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 354,249 | (119,265) | (3,555,529) | 4,213,850 | (72,154)
PEO | Thomas S. Lam [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |
PEO | Thomas S. Lam [Member] | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |
PEO | Kenneth Sim [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | (5,777,307) | (1,450,003)
PEO | Kenneth Sim [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | 5,875,819 | 1,486,991
PEO | Kenneth Sim [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | 4,920,552 | (67,429)
PEO | Kenneth Sim [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |
PEO | Kenneth Sim [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  | 4,213,850 | (72,154)
PEO | Kenneth Sim [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |
PEO | Kenneth Sim [Member] | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (5,573,539) | (2,617,300) | (880,452) | (205,730) | (204,895)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 2,299,412 | 1,818,867 | 524,690 | 652,802 | 107,514
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 25,600 | 180,624 | (956,215) | 17,308 |
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 93,191 | 155,544 | 77,967 |  | 107,266
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 132,932 | (9,656) | (1,008,267) | 2,765 |
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |
Non-PEO NEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_NonGaapMeasureDescriptionTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=asth_BrandonKSimMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=asth_ThomasSLamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=asth_KennethSimMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |